Spark Neuro

About Spark Neuro

SPARK Neuro utilizes EEG technology and AI algorithms to provide objective neurological assessments for dementia screening. The SPARK Scan significantly reduces false positive rates, enabling timely and accurate diagnoses, which can lead to earlier interventions and substantial cost savings in patient care.

```xml <problem> A significant percentage of dementia cases remain undiagnosed, leading to delayed interventions and increased healthcare costs. Existing dementia screening methods often suffer from high false positive rates, burdening physicians with unnecessary evaluations and causing undue stress for patients. Primary care physicians frequently lack the time and resources for thorough cognitive assessments. </problem> <solution> SPARK Neuro offers the SPARK Scan, an FDA-cleared, Class-II medical device that leverages EEG technology and proprietary AI algorithms to improve the accuracy and efficiency of dementia screening. The SPARK Scan provides an objective neurological assessment, significantly reducing false positive rates compared to traditional screening methods. This enables physicians to focus on patients who genuinely require further evaluation, leading to earlier and more accurate diagnoses. The non-invasive and easy-to-use device can be administered in a clinic or at home, making it accessible to a wider range of patients. By facilitating timely interventions, the SPARK Scan aims to improve patient outcomes, reduce healthcare costs, and enhance patient satisfaction. </solution> <features> - EEG-based neurological assessment for objective dementia screening - AI algorithms to analyze EEG data and identify potential indicators of cognitive impairment - Significantly reduced false positive rate (1:4) compared to traditional screening methods (4:5) - Non-invasive and safe for patients - Simple and easy to use for healthcare providers - Can be administered in a clinic or at home - Aims to enable earlier interventions and improve patient outcomes </features> <target_audience> The primary target audience includes primary care physicians, neurologists, geriatricians, and other healthcare providers involved in dementia screening and diagnosis, as well as patients at risk of or showing early signs of dementia. </target_audience> ```

What does Spark Neuro do?

SPARK Neuro utilizes EEG technology and AI algorithms to provide objective neurological assessments for dementia screening. The SPARK Scan significantly reduces false positive rates, enabling timely and accurate diagnoses, which can lead to earlier interventions and substantial cost savings in patient care.

Where is Spark Neuro located?

Spark Neuro is based in East New York, United States.

When was Spark Neuro founded?

Spark Neuro was founded in 2017.

How much funding has Spark Neuro raised?

Spark Neuro has raised 10000000.

Location
East New York, United States
Founded
2017
Funding
10000000
Employees
26 employees
Major Investors
Thiel Capital

Find Investable Startups and Competitors

Search thousands of startups using natural language

Spark Neuro

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

SPARK Neuro utilizes EEG technology and AI algorithms to provide objective neurological assessments for dementia screening. The SPARK Scan significantly reduces false positive rates, enabling timely and accurate diagnoses, which can lead to earlier interventions and substantial cost savings in patient care.

sparkneuro.com2K+
cb
Crunchbase
Founded 2017East New York, United States

Funding

$

Estimated Funding

$10M+

Major Investors

Thiel Capital

Team (25+)

No team information available.

Company Description

Problem

A significant percentage of dementia cases remain undiagnosed, leading to delayed interventions and increased healthcare costs. Existing dementia screening methods often suffer from high false positive rates, burdening physicians with unnecessary evaluations and causing undue stress for patients. Primary care physicians frequently lack the time and resources for thorough cognitive assessments.

Solution

SPARK Neuro offers the SPARK Scan, an FDA-cleared, Class-II medical device that leverages EEG technology and proprietary AI algorithms to improve the accuracy and efficiency of dementia screening. The SPARK Scan provides an objective neurological assessment, significantly reducing false positive rates compared to traditional screening methods. This enables physicians to focus on patients who genuinely require further evaluation, leading to earlier and more accurate diagnoses. The non-invasive and easy-to-use device can be administered in a clinic or at home, making it accessible to a wider range of patients. By facilitating timely interventions, the SPARK Scan aims to improve patient outcomes, reduce healthcare costs, and enhance patient satisfaction.

Features

EEG-based neurological assessment for objective dementia screening

AI algorithms to analyze EEG data and identify potential indicators of cognitive impairment

Significantly reduced false positive rate (1:4) compared to traditional screening methods (4:5)

Non-invasive and safe for patients

Simple and easy to use for healthcare providers

Can be administered in a clinic or at home

Aims to enable earlier interventions and improve patient outcomes

Target Audience

The primary target audience includes primary care physicians, neurologists, geriatricians, and other healthcare providers involved in dementia screening and diagnosis, as well as patients at risk of or showing early signs of dementia.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.